Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 12:38 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1921–1944 of 3,682 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Non-Small Cell Lung Cancer, Small Cell Lung Cancer Clear all

Conditions: Breast Cancer, Cognitive/Functional Effects, Colorectal Cancer, Lung Cancer, Prostate Cancer, Psychosocial Effects of Cancer and Its Treatment
Interventions: questionnaire administration, cognitive assessment, psychosocial assessment and care, quality-of-life assessment; Other · Procedure
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Carcinoma, Non-Small-Cell Lung, Gastric Cancer, Gastroesophageal Junction Cancer
Interventions: AZD7789; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 4
States / cities: Atlanta, Georgia • Fort Wayne, Indiana • New York, New York + 1 more

Conditions: Non-small Cell Lung Cancer
Interventions: Cetuximab; Drug
Lead sponsor: Lecia V. Sequist; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Lung Cancer
Interventions: Afatinib, Radiation, Cisplatin, Pemetrexed, Surgery; Drug · Radiation · Procedure
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2024
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Non-small Cell Lung Cancer (NSCLC), Recurrent, Non-small Cell Lung Cancer (NSCLC), Stage IV
Interventions: Erlotinib hydrochloride, Dovitinib lactate; Drug
Lead sponsor: Heather Wakelee; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Stanford, California

Conditions: Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer
Interventions: Nintedanib; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2025
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Cemiplimab, Platinum based chemotherapy, Stereotactic body radiation therapy; Drug · Radiation
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 1
States / cities: New York, New York

Conditions: HER2 Positive Solid Tumors
Interventions: SBT6050, pembrolizumab, Cemiplimab; Drug
Lead sponsor: Silverback Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 6
States / cities: Boston, Massachusetts • Durham, North Carolina • Pittsburgh, Pennsylvania + 3 more

Conditions: Lung Non-Small Cell Carcinoma
Interventions: Discussion, Questionnaire Administration; Procedure · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Stage 4 NSCLC
Interventions: Pfizer-BioNTech mRNA COVID-19 vaccine; Biological
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2035
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Anaplastic Lymphoma Kinase-positive, Carcinoma Non-small-cell Lung
Interventions: Brigatinib, Alectinib, Ceritinib, Lorlatinib, Any FDA Approved ALK Inhibitors; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Maynard, Massachusetts

Conditions: Recurrent Non-Small Cell Lung Cancer
Interventions: MV-NIS, Atezolizumab; Biological
Lead sponsor: Vyriad, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Colorectal Cancer, Depression, Esophageal Cancer, Extrahepatic Bile Duct Cancer, Fatigue, Gallbladder Cancer, Gastric Cancer, Liver Cancer, Lung Cancer, Pancreatic Cancer
Interventions: escitalopram oxalate, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 35 Years to 85 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cancer of Lung, Cancer of the Lung, Lung Cancer, Neoplasms, Lung, Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Cancer, Non-Small-Cell Lung Carcinoma
Interventions: Microwave Ablation; Device
Lead sponsor: Ethicon, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 5
States / cities: Duarte, California • Rochester, Minnesota • New York, New York + 2 more

Conditions: Non-small Cell Lung Cancer (NSCLC)
Interventions: LDK378; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 27
States / cities: Chandler, Arizona • Gilbert, Arizona • Goodyear, Arizona + 23 more

Conditions: Cancer
Interventions: management of therapy complications, massage therapy, pain therapy, psychosocial assessment and care, quality-of-life assessment; Procedure
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Non-Small-Cell Lung Adenocarcinoma, Non-small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage IV, Non-small Cell Lung Cancer Metastatic
Interventions: Docetaxel, Ganetespib; Drug
Lead sponsor: Synta Pharmaceuticals Corp.; Industry
Eligibility: 18 Years and older
Enrollment: 696 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 78
States / cities: Flagstaff, Arizona • Prescott Valley, Arizona • Sedona, Arizona + 66 more

Conditions: Adenocarcinoma of the Lung, Bronchoalveolar Cell Lung Cancer, Large Cell Lung Cancer, Squamous Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Interventions: cisplatin, etoposide, erlotinib hydrochloride, radiation therapy, docetaxel, paclitaxel, carboplatin, laboratory biomarker analysis; Drug · Radiation · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
Interventions: Cetuximab; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Newark, Delaware

Conditions: Lung Non-Squamous Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions: Biospecimen Collection, Physical Performance Testing, Questionnaire Administration; Procedure · Other
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Lung Cancer
Interventions: vinorelbine tartrate; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2007
U.S. locations: 46
States / cities: Tucson, Arizona • Fayetteville, Arkansas • Hot Springs, Arkansas + 38 more

Conditions: Advanced Solid Tumors With KRAS G12C Mutations, Solid Tumor, Adult, Unresectable Solid Tumor, Metastatic Solid Tumor, Non Small Cell Lung Cancer, KRAS G12C
Interventions: FMC-376; Drug
Lead sponsor: Frontier Medicines Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 293 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 15
States / cities: La Jolla, California • Orange, California • San Francisco, California + 11 more

Conditions: Recurrent Non-Small Cell Lung Carcinoma, Stage IB Non-Small Cell Lung Carcinoma, Stage IIA Non-Small Cell Lung Carcinoma, Stage IIB Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
Interventions: Cisplatin, CT, Docetaxel, FDG, FLT, PET/CT, Surgery; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 19 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 2
States / cities: Baltimore, Maryland • Columbus, Ohio

Conditions: Advanced Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer, Lung Neoplasms
Interventions: Vigil™, Nivolumab; Biological · Drug
Lead sponsor: Gradalis, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 3
States / cities: Abilene, Texas • Dallas, Texas • Spokane Valley, Washington

Search by objective public record fields.

Psychosocial Adjustment After Radiation Therapy in Patients With Cancer

A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer

Cetuximab as Therapy for Recurrent Non-Small Cell Lung Cancer Patients Who Have Received Prior Therapy

Afatinib With CT and RT for EGFR-Mutant NSCLC

Phase 1 Erlotinib and Dovitinib (TKI258) in Advanced Non-small Cell Lung Cancer (NSCLC)

Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer

Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC

A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors

Developing a Shared Decision Making Tool for Patients With Surgically Removed Non-small Cell Lung Cancer

Universal Immunization to Fortify Immunotherapy Efficacy and Response

A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors

Dose Escalation Trial of Intra-Tumoral Injection of NIS Measles Virus in Combination With Atezolizumab

Escitalopram in Treating Depression in Patients With Advanced Lung or Gastrointestinal Cancer

NEUWAVE Flex Microwave Ablation System in the Ablation of Primary Soft Tissue Lesions of the Lung

Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC

Massage Therapy in Treating the Symptoms of Patients With Locally Advanced or Metastatic Cancer

A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC

Erlotinib and Radiation Therapy Plus Combination Chemotherapy in Treating Patients With Inoperable Stage III Non-Small Cell Lung Cancer

An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastatic Non Small Cell Lung Carcinoma

Evaluating Modifiable Biomarkers for the Prediction of Immunotherapy Response and Toxicity

Vinorelbine in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors

A Comparison of FLT to FDG PET/CT in the Early Assessment of Chemotherapy Response in Stage IB-IIIA Resectable NSCLC

Vigil™ + Nivolumab in Advanced Non-Small Cell Lung Cancer